-
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
In the November 20th issue of the Journal of Clinical Oncology, two important articles appear, demonstrating the clinical impact of a novel therapeutic, bevacizumab, in women with recurrent ovarian cancer.
-
The Collaborative Group on Epidemiological Studies of Cervical Cancer has combined and reanalyzed any relevant data from all epidemiological studies on the association between cervical carcinoma and the pattern of oral contraceptive use.
-
Last month an article was featured in the OB/GYN Clinical Alert from the October issue of Obstetrics & Gynecology. Since the issue was rich in good material, I will go back to it to review information pertaining to one of the most common questions asked of providers"How much weight should I gain in my pregnancy?"
-
Human Papillomavirus (HPV) testing has proved efficacious in triaging minimally abnormal cytology to further investigation or surveillance. However, despite its high sensitivity for cervix pathology, its value as a primary screening technology has been formally evaluated in only a limited way.
-
-
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Because medication reconciliation is recognized as a key factor to prevention of medication-related errors, accreditation organizations require outpatient surgery programs to take steps to improve this process.